11/11/2016

HYMOVIS® Receives Permanent, Product-Specific J-Code from the Center for Medicare and Medicaid Services (CMS)

HYMOVIS® offers a convenient two-dose regimen

Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System (“HCPCS”) code, or J-Code.
The new J-Code provides reimbursement coding to healthcare professionals that administer HYMOVIS® and becomes effective on January 1, 2017.

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website



PHARMACO-VIGILANCE


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects
CLICK HERE

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine